• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

流感病毒的不同进化模式及其对疫苗研发的启示。

Distinct evolution patterns of influenza viruses and implications for vaccine development.

作者信息

Hu Ye-Fan, Zhang Bao-Zhong, Chu Hin, Huang Jian-Dong

机构信息

School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong (HKU), Hong Kong SAR, China.

BayVax Biotech Limited, Hong Kong Science Park, Hong Kong & Shenzhen BayVax Biotech Limited, Guangming, Shenzhen 518107, China.

出版信息

Innovation (Camb). 2024 Nov 28;6(1):100739. doi: 10.1016/j.xinn.2024.100739. eCollection 2025 Jan 6.

DOI:10.1016/j.xinn.2024.100739
PMID:39872480
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11763911/
Abstract

In conclusion, the distinct evolution patterns of panzootic influenza A(H5Nx) compared to A(H1N1) and A(H3N2) complicate vaccine development. Effective strategies must consider these unique patterns and the impact of pre-existing immunity. Leveraging AI-based methods for optimized antigen design is essential to mitigate the potential impact of emerging antigenically variable strains and will provide valuable insights for developing more effective vaccines to prepare for future pandemics.

摘要

总之，与甲型流感病毒A（H1N1）和A（H3N2）相比，甲型流感病毒A（H5Nx）的独特进化模式使疫苗开发变得复杂。有效的策略必须考虑这些独特模式以及既往免疫的影响。利用基于人工智能的方法进行优化抗原设计对于减轻新出现的抗原变异株的潜在影响至关重要，并将为开发更有效的疫苗以应对未来大流行提供有价值的见解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf87/11763911/69d333ccdfcd/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf87/11763911/69d333ccdfcd/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf87/11763911/69d333ccdfcd/gr1.jpg

相似文献

1
Distinct evolution patterns of influenza viruses and implications for vaccine development.流感病毒的不同进化模式及其对疫苗研发的启示。
Innovation (Camb). 2024 Nov 28;6(1):100739. doi: 10.1016/j.xinn.2024.100739. eCollection 2025 Jan 6.
2
Bivalent H1 and H3 COBRA Recombinant Hemagglutinin Vaccines Elicit Seroprotective Antibodies against H1N1 and H3N2 Influenza Viruses from 2009 to 2019.二价 H1 和 H3 COBRA 重组血凝素疫苗可诱导针对 2009 年至 2019 年 H1N1 和 H3N2 流感病毒的血清保护性抗体。
J Virol. 2022 Apr 13;96(7):e0165221. doi: 10.1128/jvi.01652-21. Epub 2022 Mar 15.
3
Comparison of Adjuvanted-Whole Inactivated Virus and Live-Attenuated Virus Vaccines against Challenge with Contemporary, Antigenically Distinct H3N2 Influenza A Viruses.佐剂全灭活病毒与减毒活病毒疫苗对当代抗原性不同的 H3N2 流感 A 病毒挑战的比较。
J Virol. 2018 Oct 29;92(22). doi: 10.1128/JVI.01323-18. Print 2018 Nov 15.
4
mRNA vaccines encoding computationally optimized hemagglutinin elicit protective antibodies against future antigenically drifted H1N1 and H3N2 influenza viruses isolated between 2018-2020.mRNA 疫苗编码经计算优化的血凝素，可诱导针对 2018-2020 年期间分离的未来抗原漂移的 H1N1 和 H3N2 流感病毒的保护性抗体。
Front Immunol. 2024 Mar 12;15:1334670. doi: 10.3389/fimmu.2024.1334670. eCollection 2024.
5
Elicitation of Protective Antibodies against 20 Years of Future H3N2 Cocirculating Influenza Virus Variants in Ferrets Preimmune to Historical H3N2 Influenza Viruses.在对历史 H3N2 流感病毒无预存免疫的雪貂中引发针对未来 20 年 H3N2 共循环流感病毒变异株的保护性抗体。
J Virol. 2019 Jan 17;93(3). doi: 10.1128/JVI.00946-18. Print 2019 Feb 1.
6
Novel influenza vaccine M2SR protects against drifted H1N1 and H3N2 influenza virus challenge in ferrets with pre-existing immunity.新型流感疫苗 M2SR 可预防具有预先存在免疫的雪貂感染 drifted H1N1 和 H3N2 流感病毒。
Vaccine. 2018 Aug 9;36(33):5097-5103. doi: 10.1016/j.vaccine.2018.06.053. Epub 2018 Jul 13.
7
Pandemic influenza 1918 H1N1 and 1968 H3N2 DNA vaccines induce cross-reactive immunity in ferrets against infection with viruses drifted for decades.1918 年 H1N1 大流行流感和 1968 年 H3N2 流感的 DNA 疫苗可诱导雪貂对经过几十年漂移的病毒感染产生交叉反应性免疫。
Influenza Other Respir Viruses. 2011 Jan;5(1):13-23. doi: 10.1111/j.1750-2659.2010.00177.x. Epub 2010 Nov 3.
8
Novel Reassortant Human-Like H3N2 and H3N1 Influenza A Viruses Detected in Pigs Are Virulent and Antigenically Distinct from Swine Viruses Endemic to the United States.在猪身上检测到的新型重配人源化H3N2和H3N1甲型流感病毒具有致病性，且在抗原性上与美国流行的猪病毒不同。
J Virol. 2015 Nov;89(22):11213-22. doi: 10.1128/JVI.01675-15. Epub 2015 Aug 26.
9
Predominance of influenza virus A(H3N2) 3C.2a1b and A(H1N1)pdm09 6B.1A5A genetic subclades in the WHO European Region, 2018-2019.2018-2019 年，世卫组织欧洲区域甲型流感病毒 A(H3N2)3C.2a1b 和 A(H1N1)pdm09 6B.1A5A 基因亚系占主导地位。
Vaccine. 2020 Jul 31;38(35):5707-5717. doi: 10.1016/j.vaccine.2020.06.031. Epub 2020 Jul 3.
10
Antigenic and genetic variation in the hemagglutinins of H1N1 and H3N2 human influenza a viruses in the Shanghai area from 2005 to 2008.2005 年至 2008 年期间上海地区 H1N1 和 H3N2 人甲型流感病毒血凝素的抗原和遗传变异。
J Med Virol. 2011 Jul;83(7):1113-20. doi: 10.1002/jmv.22078. Epub 2011 Apr 22.

引用本文的文献

1
A novel C-3-substituted oleanolic acid benzyl amide derivative exhibits therapeutic potential against influenza A by targeting PA-PB1 interactions and modulating host macrophage inflammation.一种新型的C-3-取代齐墩果酸苄基酰胺衍生物通过靶向PA-PB1相互作用和调节宿主巨噬细胞炎症，展现出抗甲型流感的治疗潜力。
Acta Pharm Sin B. 2025 Aug;15(8):4156-4173. doi: 10.1016/j.apsb.2025.05.031. Epub 2025 May 29.
2
Evolving SARS-CoV-2 Vaccines: From Current Solutions to Broad-Spectrum Protection.不断演变的新冠病毒疫苗：从当前解决方案到广谱保护
Vaccines (Basel). 2025 Jun 12;13(6):635. doi: 10.3390/vaccines13060635.

本文引用的文献

1
Rational design of a booster vaccine against COVID-19 based on antigenic distance.基于抗原距离的 COVID-19 增强型疫苗的合理设计。
Cell Host Microbe. 2023 Aug 9;31(8):1301-1316.e8. doi: 10.1016/j.chom.2023.07.004. Epub 2023 Jul 31.
2
Is a Universal Influenza Virus Vaccine Possible?通用流感病毒疫苗是否可行？
Annu Rev Med. 2020 Jan 27;71:315-327. doi: 10.1146/annurev-med-120617-041310. Epub 2019 Oct 10.
3
Antibody landscapes after influenza virus infection or vaccination.流感病毒感染或接种疫苗后的抗体图谱。
Science. 2014 Nov 21;346(6212):996-1000. doi: 10.1126/science.1256427.
4
Viral phylodynamics.病毒系统发生学。
PLoS Comput Biol. 2013;9(3):e1002947. doi: 10.1371/journal.pcbi.1002947. Epub 2013 Mar 21.